RxDoctor Payments Data

Lauren Phillips

Nurse Practitioner · Toledo, OHNPI 1598900516

Payments from drug & device makers

$2,549in general payments, 2019–2025

Across 78 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$343
  • Dexcom, Inc.$317
  • Sanofi-aventis U.S. LLC$310
  • Novo Nordisk$252
  • Sequel Med Tech, LLC$241
  • AstraZeneca$193
  • plus $893 from 12 others

What the payments were for

  • Food & beverage$2,549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,549 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$61,399
Medicare patients
330
Services billed
1,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide436$559,108
TrulicityDulaglutide267$340,233
JardianceEmpagliflozin245$287,699
MounjaroTirzepatide214$267,706
FarxigaDapagliflozin Propanediol190$216,138
Somatuline DepotLanreotide Acetate14$131,721
JanuviaSitagliptin Phosphate98$112,976
Tresiba Flextouch U-200Insulin Degludec50$82,321
Fiasp FlextouchInsulin Aspart (Niacinamide)76$79,584
Lantus SolostarInsulin Glargine,hum.Rec.Anlog314$73,443
Humalog Kwikpen U-100Insulin Lispro151$62,730
Tresiba Flextouch U-100Insulin Degludec67$54,194
RybelsusSemaglutide34$53,232
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$49,322
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$47,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$252$618,594489 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$66$613,926493 claims
AstraZenecaFarxiga$193$216,138190 claims
AbbVieArmour Thyroid$343$2,52527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →